← Eichor
Condition: Benign Breast Tumors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Benign Breast Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT05463796
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168
Photo-Acoustic and Ultrasonographic Mammoscope
Phase 2 · 1 location(s) · Franciscus Gasthuis & Vlietland (Hospital) · NCT07492589
A Novel Approach in the Evaluation of Breast Masses With Doppler US
Phase N/A · 1 location(s) · Ahmet Yesildag · NCT07465523
VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Eva
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06878547
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)
Phase N/A · 1 location(s) · iSono Health, Inc. · NCT07505797
Clinical Explorative Optical Breast Investigations
NA · 1 location(s) · Region Skane · NCT06857669
A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignan
Phase N/A · 1 location(s) · Hubei Cancer Hospital · NCT07250204
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.